Why ImmunityBio Stock Is Skyrocketing Again Today
Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (NASDAQ: IBRX), spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible slate of good news. This morning, the company announced two bits of great news. First, enrollment for the company's Anktiva therapy exceeded expectations in a trial when treating non-muscle-invasive bladder cancer. This development means ImmunityBio could submit a biologics licensing agreement to the FDA by year's end.
Second, another clinical trial showed that the company's CAR-NK therapy demonstrated 100% disease control in its first four patients with Non-Hodgkin lymphoma. This update could have significant, longer-term implications for ImmunityBio as it develops next-gen therapies beyond its first hit, Anktiva.
These fantastic updates occur just:
Source Fool.com
ImmunityBio Inc. Aktie
Leichtes Buy-Übergewicht bei der ImmunityBio Inc. Aktie mit 3 zu 1 Einschätzungen.
Ein unerwartetes Potenzial von -41.28% für ImmunityBio Inc., obwohl das Kursziel von 4 € den aktuellen Kurs von 6.81 € unterschreitet.
